With ORKAMBI®▼ (lumacaftor/ivacaftor) you can now treat cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene1
Information on cystic fibrosis-causing mutations
Information about ORKAMBI® phase III clinical trials
Information about KALYDECO® phase III clinical trials
1. ORKAMBI® Summary of Product Characteristics. February 2018. Vertex Pharmaceuticals (Europe) Limited.